



COMPANY PRESENTATION

H1 2023



HIGHLIGHTS H1 2023

CONTINUING ON GROWTH TRACK

- Significant **increase in revenue and earnings**
- **Well balanced sales development** across all product categories and business fields
- **Order intake** on last year's high level and strong **order book**
- Preparing to exploit the potential in target markets even more by **investing in R&D for semiconductor inspection**, among other things



UPDATE ON ESG

INCREASING OUR ON-SITE ELECTRICITY GENERATION LEVEL

- Completed review of existing properties for PV suitability
- Potential to **increase in-house generation to 1.3 GWh - from 2% to 20% of consumption**
- Capex **EUR 1.7 m**
- Contracts awarded - Completion expected Q4 2023
- Reduction of CO₂ emissions by **600 t per year**



Net carbon neutral
by 2024 (Scope 1+2)



NEW SITE IN ITALY

BUILDING UP CAPACITY FOR OUR AMBITIOUS GROWTH PLANS

- Current site is rented and unsuitable
 - Construction of a **new production facility in Schio (Italy)** commenced in June '23
 - Flexibility to produce all types of vacuum vessels
 - 5,000m² - **up to 35% higher capacity**
 - Total **Capex** – c. **EUR 8,75 m**
 - **Completion and inauguration** expected in **Summer 2024**
- **Production facility and logistics center in Wetttemberg (Germany)** - progressing as planned

KEY FIGURES FOR H1 2023

GROWTH MOMENTUM LARGELY INTACT

Order Intake

EUR 104.9 m

↘ 1%

Sales

EUR 126.7 m

↗ 58.2%

Order Backlog

EUR 298.3 m

↘ 3.6%

EBITDA

EUR 17.4 m


↗ 83.7%

- Order intake virtually at prior year level (-1%), book-to-bill ratio at 0.83x
- High order backlog with nearly EUR 300 m (-3.6%), providing visibility until 2025
- Financial momentum continued in H1 2023: Sales are up 58.2% y/y, EBITDA +83.7% y/y


ORDER INTAKE

HEALTHY DISTRIBUTION ACROSS REGIONS AND PRODUCTS

Year to Year
[EURm]



Region
[EURm]




- Order intake on prior year level
- Well diversified order book: **Asia 33%, Germany 15%, Europe (ex-Germany) 38%, America 14%**
- **Semiconductor** contributes **71.5%** of new orders, **Industrial 28.5%**

GROUP SALES

CONTINUOUS STRONG GROWTH IN BOTH SEGMENTS

Year to Year
[EURm]

Segment Split
[EURm]




- **Strong growth continued** in H1, with sales increasing by **58.2% y/y**
- Both divisions benefit from **megatrends**, e.g. **digitization, e-mobility, renewable energies**
- Industrial benefits from high demand for infrastructure (hydrogen/LNG) projects

GROUP PROFIT

EBITDA AND EBIT SIGNIFICANTLY OUTPACING SALES GROWTH


Gross Profit

[EURm]




EBITDA

[EURm]



EBIT


[EURm]




QUARTERLY DEVELOPMENT

MARGIN IMPROVEMENT VS. PREVIOUS YEAR AS WELL AS PREVIOUS QUARTER


Sales
[EURm]



EBITDA
[EURm]



EBIT
[EURm]




SEMICONDUCTOR

STRONG REVENUE GROWTH AND SUBSTANTIAL EBIT-MARGIN IMPROVEMENT


Sales and EBIT margin

[EURm]




Order intake

[EURm]



Order backlog

[EURm]




INDUSTRIAL

HIGH DEMAND FROM INFRASTRUCTURE (H/LNG)


Sales and EBIT margin

[EURm]




Order intake

[EURm]



Order backlog

[EURm]



FINANCIAL GUIDANCE FOR FULL YEAR 2023

DOUBLE-DIGIT GROWTH

Consolidated sales expected between
EUR 240 and 260 million

CONTINUED PROFITABILITY

Operating result before taxes and depreciation
and amortisation (EBITDA) between
EUR 36 and 40 million



TIME FOR YOUR
QUESTIONS





This presentation contains forward-looking statements which are based on certain assumptions, expectations and opinions of the management of PVA TePla (the "Company") or cited from third-party sources. These statements are, therefore, subject to certain known or unknown risks and uncertainties. A variety of factors, many of which are beyond the Company's control, affect the Company's business activities, business strategy, results, performance and achievements. Should one or more of these factors or risks or uncertainties materialize, actual results, performance or achievements of the Company may vary materially from those expressed or implied as being expected, anticipated, intended, planned, believed, sought, estimated or projected in the relevant forward-looking statement.

The Company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does the Company accept any responsibility for the actual occurrence of the forecasted developments. The Company neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

Where any information and statistics are quoted from any external source, such information or statistics should not be interpreted as having been adopted or endorsed by the Company as being accurate. This presentation is dated as of 28 November 2022. Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. This material is being delivered in conjunction with an oral presentation by the Company and should not be taken out of context.